Cargando…
Mesencure—an enhanced cell therapy explicitly developed for treating acute respiratory distress in covid-19: from benchtop to bedside
Autores principales: | Bronshtein, T., Ben David, D., Novak, A., Kivity, V., Hamoud, S., Hayek, T., Meretzki, S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Society for Cell & Gene Therapy. Published by Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8111922/ http://dx.doi.org/10.1016/S1465324921002784 |
Ejemplares similares
-
Possible Divergent Local and Peripheral Immunological Effects of Low-Dose Mesencure, an Enhanced Mesenchymal Cell Therapy, May Contribute to Its Success in Treating Severe Covid-19 Patients
por: Bronshtein, Tomer, et al.
Publicado: (2021) -
Mesenchymal Stem/Stromal Cells: MESENCURE: A PROFESSIONALIZED CELL THERAPY FOR ARDS REDUCED THE MORTALITY OF SEVERE COVID-19 PATIENTS BY 68% ACCORDING TO A RECENTLY CONCLUDED MULTI-CENTER, CONTROLLED PHASE II STUDY
por: Bronshtein, T., et al.
Publicado: (2022) -
Stem Cells in Musculoskeletal Regeneration: From Benchtop to Bedside
por: Fan, Jiabing, et al.
Publicado: (2016) -
From Benchtop to Bedside: A Review of Oncolytic Virotherapy
por: Choi, Audrey H., et al.
Publicado: (2016) -
Leber's Hereditary Optic Neuropathy-Gene Therapy: From Benchtop to Bedside
por: Koilkonda, Rajeshwari D., et al.
Publicado: (2011)